# BioAffinity Technologies Inc. (BIAF)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $3M  
**Price:** $1.63 (+7.24%)

> BioAffinity Technologies Inc. is a biotechnology company specializing in noninvasive diagnostics and targeted cancer therapeutics for early-stage lung cancer and other lung diseases. Its flagship product, CyPath Lung, employs flow cytometry technology and automated AI analysis to examine sputum samples, identifying cell populations indicative of malignancy, including cancer cells shed from lung tumors. This enables early detection in high-risk patients, potentially reducing the need for invasive biopsies. The company operates through Diagnostic Research and Development and Laboratory Services segments, with its Precision Pathology Laboratory Services providing anatomic and clinical pathology support. BioAffinity Technologies Inc. also advances its platform technology for applications in asthma and COPD, such as matching patients to biologic therapies by detecting antibody drug receptors in sputum. Additionally, through its subsidiary OncoSelect Therapeutics, it researches porphyrin-based therapies that selectively target and kill cancer cells. Founded in 2014 and headquartered in San Antonio, Texas, BioAffinity Technologies Inc. plays a key role in the in vitro diagnostics sector of healthcare, addressing critical needs in oncology and respiratory medicine.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $6M | — | -$11M | -$15M | — |
| 2024 | $9M | — | -$9M | -$9M | — |
| 2023 | $3M | — | -$8M | -$8M | — |
| 2022 | $4,803 | $4,336 | -$4M | -$8M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $11M | $4M | $7M | $6M | — |
| 2024 | $7M | $4M | $3M | $1M | — |
| 2023 | $8M | $3M | $5M | $3M | — |
| 2022 | $12M | $1M | $11M | $11M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$9M | $60,568 | -$9M |
| 2024 | -$7M | $79,083 | -$7M |
| 2023 | -$6M | $22,902 | -$6M |
| 2022 | -$4M | $219,987 | -$4M |
| 2021 | -$2M | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/BIAF)